Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.

ABSTRACT:

Objective

To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk.

Methods

The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study was a double-blind, randomized, placebo-controlled clinical trial using a 2 × 2 factorial design. Participants without known cardiovascular disease or need for treatment were randomized to candesartan (16 mg) plus hydrochlorothiazide (12.5 mg) or placebo and to rosuvastatin (10 mg) or placebo. Participants who were ≥70 years of age completed the Digit Symbol Substitution Test (DSST), the modified Montreal Cognitive Assessment, and the Trail Making Test Part B at baseline and study end.

Results

Cognitive as

SUBMITTER: Bosch J 

PROVIDER: S-EPMC6453765 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature